IP Library Granted Patent US 9,611,292
Granted Patent B2
US 9,611,292 · App. 14/113,763 · Granted Apr 4, 2017

Peptide inhibitors of serotonin 5-HT2c receptors:PTEN interaction

Inventors: Kathryn Cunningham (Galveston, TX); Scott Gilbertson (Houston, TX)
Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
C07K7/06A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,611,292
App. No.
14/113,763
Granted
Apr 4, 2017
Kind
B2
Abstract

The 5-HT 2C receptor is implicated in feeding, obesity, palatable food reward, metabolic disorders, drug addiction, anxiety, stress sensitivity, and depression. Embodiments of the invention are directed to modulation of the 5-HT 2cR. Certain aspects are directed to therapies for the above referenced conditions. In certain aspects, therapeutic agents are identified that disrupt the 5-HT2cR:PTEN complex activating 5-HT2CR signaling. In certain aspects the complex is disrupted by a disrupter. The disrupter can be a peptide that displaces PTEN from the 5-HT 2cR:PTEN complex or inhibits the formation of the complex.

Claims (6)

1. A 5-HT 2c R: PTEN disrupter peptide consisting of the amino acid sequence of SEQ ID NO: 2, wherein the peptide has been modified by an amino terminal modification, a carboxy terminal modification, or an amino terminal modification and a carboxy terminal modification; or a functional variant thereof wherein the functional variant has a single amino acid substitution within the amino acid sequence of SEQ ID NO :2.

2. The peptide of claim 1 , wherein the functional variant has an amino acid sequence consisting of the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

3. The peptide of claim 1 , wherein the peptide has the amino acid sequence of SEQ ID NO: 2.

4. The peptide of claim 1 , further comprising a label.

5. The peptide of claim 1 , wherein the amino terminal modification is acylation, biotinylation, or detectable label.

6. The peptide of claim 1 , wherein the carboxy terminal modification is acylation, amination, or biotinylation.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2017
From: GILBERTSON, SCOTT
To: THE UNIVERSITY OF HOUSTON SYSTEM
Reel/Frame 042130/0066 →
CONFIRMATORY LICENSE Recorded Jan 3, 2017
From: UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041231/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2013
From: CUNNINGHAM, KATHRYN A.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 031723/0009 →
Continuity (2)
Provisional Application 61479837 · Apr 27, 2011
Related Publication 20140235546A1 · Aug 21, 2014